User login

RESSTORE: a Multicentric and European clinical trial 2015-2020

RESSTORE, REgenerative Stem cell therapy for STroke in Europe, is a multicentric project in Personalising health and care (PHC) area financed by the European Commission H2020 programme. The RESSTORE project is focused on the assessment of the efficacy of intravenous cell therapy to improve recovery and/or compensation after ischemic stroke. The RESSTORE consortium consists of 28 partners, including 23 clinical centers, 5 cell therapy units, 5 experimental laboratories, 1 Clinical Research Organisation. The project, co-coordinated by Dr Olivier Detante (CHU Grenoble, France) and Pr Exuperio DIEZ TEJEDOR (SERMAS, Madrid, Spain), will recruit 400 patients from the Czech Republic, Finland, France, Spain, Scotland and deliver new knowledge on the fast growing area of regenerative medicine. The project started in September 2015 and will receive funding from the European Commission for 5 years.

Disclaimer: The RESSTORE project and associated cell therapy is an experimental study with a well defined scientific scope which adheres to the most stringent regulatory and ethical requirements. Patient recruitment follows a strict procedure (inclusion/exclusion criteria according to a large range of variables), applied by clinical experts in all partnering centres to meet the boundaries defined in the study protocol. 

The RESSTORE cellular therapy is (as one of the major inclusion criterias amongst several others) specifically targeted to individuals who suffered from a particular type of stroke (hemispheric, ischemic stroke) and who can be enroled in the study after 1-4 days post-stroke

NCT number: NCT02849613 and EudraCT number: 2016-001902-40

Latest news

This year, RESSTORE Progress Meeting will take place in Seville on 6th and 7th November 2017. Workpackages progress will be presented to the whole consortium and workshops will be organised. 

The first RESSTORE progress meeting took place on the 6th and 7th of October 2016 in the Chateau de Montchât, in Lyon (France). This event allowed partners to follow all current ongoing activities on the project, review in-depth the clinical trial protocol with the input of expert clinicians as well as discuss any potential bottlenecks that should be overcome. The project is on track - all authorisations required to launch the clinical trial are being gathered while all necessary links between all participating clinical centers, cell manufacturing groups and Medfiles -the CRO in charge of all operationnel aspects of the trial - are now in place.